Abstract Details
|
Shruti N. Iyer, MBBS
PRESENTER |
Dr. Iyer has nothing to disclose. |
| Gabriela Figueiredo Pucci, MD | Dr. Figueiredo Pucci has nothing to disclose. |
| Katherine McFarlane, MS (University of Pittsburgh) | Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace. |
| Alex Israel, MD | Dr. Israel has nothing to disclose. |
| DANIELLE R. CARNS, PsyD | Dr. CARNS has nothing to disclose. |
| LIANNE G. Vighetti, DHCE, HEC-C, LCSW | Dr. Vighetti has nothing to disclose. |
| Brittany W. Concilus, LCSW | Miss Concilus has nothing to disclose. |
| Wesley Kerr, MD, PhD (University of Pittsburgh) | Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from 好色先生. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care. |